为探究 Edaravone 对失神癫痫的作用，研究人员在 WAG/Rij 大鼠（失神癫痫遗传动物模型）中开展研究。给 28 只大鼠分 4 组（对照、1/10/30 mg/kg Edaravone 处理），记录 ECoG 并检测脑内 TAS、TOS、TNF-α。结果低剂量减少 SWDs，高剂量增加，低剂量调节氧化应激和炎症。

胶质母细胞瘤是侵袭性脑肿瘤，中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号，而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此，加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生，并延长临床前模型的寿命 ...

Living in the moment takes a lot of practice. ALS makes the past a place to visit for short periods of time, but dwelling on the future for too long can create an unbearable fear. That’s why it’s so ...

Discover comprehensive details about Edaravone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

SAVANNAH, Ga. -- Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS), a phase IIIb trial showed. Both on/off dosing and ...

Indeed, in cell cultures in the lab, Edaravone inhibited BTSC growth at low concentrations and caused cell death at higher concentrations, whereas normal brain stem cells were relatively unaffected.

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy. It has become clear in ...

Oral edaravone for patients with amyotrophic lateral sclerosis (ALS) is safe through a total of 144 weeks with no new safety signals observed. Among patients with amyotrophic lateral sclerosis ...

IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer ...

The presentations will provide insights into patient demographics, treatment duration, progression milestones and healthcare resource utilization data among RADICAVA ORS ® (edaravone)-treated ...

At 2 years, more untreated controls died than those treated with IV edaravone. Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV ...

Based on study data, a staggered edaravone regimen is most appropriate for those with ALS. For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved ...